FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

Re-evaluating the Incidence of Tysabri (Natalizumab)-Associated Progressive Multifocal Leukoencephalopathy: STUDY














































Image Source: RYO1M


Abstract

Objective:
To estimate the prospective risk of developing PML during therapy with natalizumab in JCV-seropositive patients.

Methods:
We analyzed postmarketing data about the incidence of PML on natalizumab and quantified the risks by either applying the Kaplan-Meier estimator or, where this was not possible due to the unavailability of the respective raw data, using formulae yielding very similar figures.

Results:
In JCV-seropositive patients with prior immunosuppressive treatment, the PML risk for months 25–48 of natalizumab therapy is about 19.5 per thousand. Without previous exposure to immunosuppressants, the risk during months 25–48 is approximately 7.4 per thousand, and for months 49–72, it is approximately 10.8 per thousand. If one additionally assumes that the JCV index is in the range 0.9–1.5, then the incidence for months 49–72 is around 6.2 per thousand in comparison to 17.0 per thousand when the JCV index exceeds 1.5.

Conclusions:
Biogen’s statistics concerning the risk of PML on natalizumab treatment, while in principle helpful, underestimate the true incidence systematically and significantly. Realistic estimates of the longterm risk are nearly double those previously published, with some patient groups carrying a risk that is almost nine times higher. Fortunately, a refined risk-stratification algorithm with the incorporation of such measures as l-selectin and CSF lipid-specific antibodies has the potential to make natalizumab a considerably safer drug.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISANDRELATEDDISORDERS
Note: Materials may be edited for content and length
Click here to read original article

Labels: , , ,



Go to Newer News Go to Older News